nach oben

Current Neurology and Neuroscience Reports

Erschienen in:

01.10.2021 | Dementia (K.S. Marder, Section Editor)

Molecular Imaging of the Cholinergic System in Alzheimer and Lewy Body Dementias: Expanding Views

verfasst von: Prabesh Kanel, Marc-André Bedard, Meghmik Aghourian, Pedro Rosa-Neto, Jean-Paul Soucy, Roger L. Albin, Nicolaas I. Bohnen

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 10/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Brain cholinergic denervation is a major feature of Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB). We reviewed the topography assessed by a cholinergic molecular imaging study in these two major types of dementia. A small meta-analysis directly comparing vesicular acetylcholine transporter (VAChT) PET scans of AD vs. DLB patients is presented.

Recent Findings

VAChT PET studies showed evidence of extensive cortical cholinergic denervation in both forms of dementia, while multiple subcortical structures were also in DLB. Novel analysis revealed evidence of metathalamic denervation in AD, and epithalamus, premotor/sensorimotor cortical, and striatal losses in DLB.

Summary

Topographically distinct cortical and subcortical cholinergic lesions can distinguish AD and DLB, and new structures have been highlighted here. Differential vulnerability of specific cholinergic projections is likely associated with specific clinical features of these disorders. Improved understanding of the mechanisms and roles of cholinergic neurotransmission in regions with cholinergic deficits may lead to symptomatic therapies.

Bohnen NI, Grothe MJ, Ray NJ, Muller MLTM, Teipel SJ. Recent advances in cholinergic imaging and cognitive decline-revisiting the cholinergic hypothesis of dementia. Curr Geriatr Rep. 2018;7(1):1–11. https://doi.org/10.1007/s13670-018-0234-4.CrossRefPubMedPubMedCentral

Sarter M, Lustig C, Howe WM, Gritton H, Berry AS. Deterministic functions of cortical acetylcholine. Eur J Neurosci. 2014;39(11):1912–20. https://doi.org/10.1111/ejn.12515.CrossRefPubMedPubMedCentral

Gombkoto P, Gielow M, Varsanyi P, Chavez C, Zaborszky L. Contribution of the basal forebrain to corticocortical network interactions. Brain Struct Funct. 2021. https://doi.org/10.1007/s00429-021-02290-z.

Petrou M, Frey KA, Kilbourn MR, Scott PJ, Raffel DM, Bohnen NI, et al. In vivo imaging of human cholinergic nerve terminals with (-)-5-¹⁸F-fluoroethoxybenzovesamicol: biodistribution, dosimetry, and tracer kinetic analyses. J Nucl Med Off Publ Soc Nucl Med. 2014;55(3):396–404. https://doi.org/10.2967/jnumed.113.124792.CrossRef

Albin RL, Bohnen NI, Muller M, Dauer WT, Sarter M, Frey KA, et al. Regional vesicular acetylcholine transporter distribution in human brain: a [(18) F]fluoroethoxybenzovesamicol positron emission tomography study. J Compar Neurol. 2018. https://doi.org/10.1002/cne.24541.

Mesulam MM. Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer’s disease. J Comp Neurol. 2013;521(18):4124–44. https://doi.org/10.1002/cne.23415.CrossRefPubMedPubMedCentral

Arciniegas DB. Cholinergic dysfunction and cognitive impairment after traumatic brain injury Part 1: the structure and function of cerebral cholinergic systems. J Head Trauma Rehab. 2011;26(1):98–101. https://doi.org/10.1097/HTR.0b013e31820516cb.CrossRef

Zhang C, Zhou P, Yuan T. The cholinergic system in the cerebellum: from structure to function. Rev Neurosci. 2016;27(8):769–76. https://doi.org/10.1515/revneuro-2016-0008.CrossRefPubMed

Abudukeyoumu N, Hernandez-Flores T, Garcia-Munoz M, Arbuthnott GW. Cholinergic modulation of striatal microcircuits. Eur J Neurosci. 2019;49(5):604–22. https://doi.org/10.1111/ejn.13949.CrossRefPubMed

10.•

Aghourian M, Legault-Denis C, Soucy JP, Rosa-Neto P, Gauthier S, Kostikov A, et al. Quantification of brain cholinergic denervation in Alzheimer’s disease using PET imaging with [(18)F]-FEOBV. Mol Psychiatry. 2017;22(11):1531–8. https://doi.org/10.1038/mp.2017.183. This study reports the first detailed FEOBV PET analysis in patients with AD and reported widespread cortical reductions in VAChT binding.

11.

Liu AK, Chang RC, Pearce RK, Gentleman SM. Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer’s and Parkinson’s disease. Acta Neuropathol. 2015;129(4):527–40. https://doi.org/10.1007/s00401-015-1392-5.CrossRefPubMedPubMedCentral

12.

Schmitz TW, Mur M, Aghourian M, Bedard MA, Spreng RN. Alzheimer’s Disease Neuroimaging I Longitudinal Alzheimer’s degeneration reflects the spatial topography of cholinergic basal forebrain projections. Cell reports. 2018;24(1):38–46. https://doi.org/10.1016/j.celrep.2018.06.001.CrossRefPubMed

13.

Lehericy S, Hirsch EC, Cervera-Pierot P, Hersh LB, Bakchine S, Piette F, et al. Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer’s disease. J Comp Neurol. 1993;330(1):15–31. https://doi.org/10.1002/cne.903300103.CrossRefPubMed

14.••

Mazere J, Lamare F, Allard M, Fernandez P, Mayo W. ¹²³I-Iodobenzovesamicol SPECT imaging of cholinergic systems in dementia with Lewy bodies. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017;58(1):123–8. https://doi.org/10.2967/jnumed.116.176180. First VAChT SPECT study in DLB.

15.••

Nejad-Davarani S, Koeppe RA, Albin RL, Frey KA, Muller M, Bohnen NI. Quantification of brain cholinergic denervation in dementia with Lewy bodies using PET imaging with [(18)F]-FEOBV. Mol Psychiatry. 2019;24(3):322–7. https://doi.org/10.1038/s41380-018-0130-5. This study reported VAChT binding losses in patients with DLB in the whole neocortex, hippocampus, amygdala, thalamus, basal ganglia, vermis, and dorsal pontomesenchephalic region.

16.•

Kanel P, Müller MLTM, van der Zee S, Sanchez-Catasus CA, Koeppe RA, Frey KA, et al. Topography of cholinergic changes in dementia with Lewy bodies and key neural network hubs. J Neuropsychiatry Clin Neurosci. 2020;32(4):370–5. https://doi.org/10.1176/appi.neuropsych.19070165. The authors used a different imaging analysis method (whole brain voxel-based analyses) and found a distinct topographic pattern of VAChT binding losses in patients with DLB. Regionally more prominent losses were seen in the bilateral opercula, anterior-to-mid cingulate cortices, bilateral insula, bilateral geniculate nuclei, pulvinar, right proximal optic radiation, bilateral anterior and superior thalami, and posterior hippocampal fimbria and fornix.

17.

Habeck C, Krakauer JW, Ghez C, Sackeim HA, Eidelberg D, Stern Y, et al. A new approach to spatial covariance modeling of functional brain imaging data: ordinal trend analysis. Neural Comput. 2005;17(7):1602–45. https://doi.org/10.1162/0899766053723023.CrossRefPubMed

18.

Schumacher J, Gunter JL, Przybelski SA, Jones DT, Graff-Radford J, Savica R, et al. Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. Brain. 2021. https://doi.org/10.1093/brain/awab218.

19.

Halassa MM, Kastner S. Thalamic functions in distributed cognitive control. Nat Neurosci. 2017;20(12):1669–79. https://doi.org/10.1038/s41593-017-0020-1.CrossRefPubMed

20.

Mihai PG, Moerel M, de Martino F, Trampel R, Kiebel S, von Kriegstein K. Modulation of tonotopic ventral medial geniculate body is behaviorally relevant for speech recognition. Elife. 2019;8. https://doi.org/10.7554/eLife.44837.

21.

Phansuwan-Pujito P, Møller M, Govitrapong P. Cholinergic innervation and function in the mammalian pineal gland. Microsc Res Tech. 1999;46(4–5):281–95. https://doi.org/10.1002/(sici)1097-0029(19990815/01)46:4/5%3c281::Aid-jemt5%3e3.0.Co;2-n.CrossRefPubMed

22.

Heckers S, Geula C, Mesulam M. Cholinergic innervation of the human thalamus: dual origin and differential nuclear distribution. J Comp Neurol. 1992;325:68–82.CrossRefPubMed

23.

Lee SH, Cho H, Choi JY, Lee JH, Ryu YH, Lee MS, et al. Distinct patterns of amyloid-dependent tau accumulation in Lewy body diseases. Movement Disorders Off J Movement Disorder Soc. 2018;33(2):262–72. https://doi.org/10.1002/mds.27252.CrossRef

24.

Seidel K, Bouzrou M, Heidemann N, Krüger R, Schöls L, den Dunnen WFA, et al. Involvement of the cerebellum in Parkinson disease and dementia with Lewy bodies. Ann Neurol. 2017;81(6):898–903. https://doi.org/10.1002/ana.24937.CrossRefPubMed

25.

Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol. 2003;60(12):1745–8. https://doi.org/10.1001/archneur.60.12.1745.CrossRefPubMed

26.

Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer’s disease, and Parkinson’s disease. Ann Neurol. 1996;40(3):399–410. https://doi.org/10.1002/ana.410400309.CrossRefPubMed

27.

Hirano S, Shinotoh H, Shimada H, Ota T, Sato K, Tanaka N, et al. Voxel-based acetylcholinesterase PET study in early and late onset Alzheimer’s disease. J Alzheimers Dis. 2018;62(4):1539–48. https://doi.org/10.3233/jad-170749.CrossRefPubMed

28.

Hanna Al-Shaikh FS, Duara R, Crook JE, Lesser ER, Schaeverbeke J, Hinkle KM, et al. Selective vulnerability of the nucleus basalis of Meynert among neuropathologic subtypes of Alzheimer disease. JAMA Neurol. 2020;77(2):225–33. https://doi.org/10.1001/jamaneurol.2019.3606.CrossRefPubMed

29.

Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology. 2005;65(11):1716–22. https://doi.org/10.1212/01.wnl.0000191154.78131.f6.CrossRefPubMed

30.

van der Zee S, Vállez García D, Elsinga PH, Willemsen ATM, Boersma HH, Gerritsen MJJ, et al. [¹⁸F]Fluoroethoxybenzovesamicol in Parkinson’s disease patients: quantification of a novel cholinergic positron emission tomography tracer. Movement Disorders Off J Movement Disorder Soc. 2019;34(6):924–6. https://doi.org/10.1002/mds.27698.CrossRef

31.

van der Zee S, Muller M, Kanel P, van Laar T, Bohnen NI. Cholinergic denervation patterns across cognitive domains in Parkinson’s disease. Movement Disorders Off J Movement Disorder Soc. 2021;36(3):642–50. https://doi.org/10.1002/mds.28360.CrossRef

32.

Fu H, Hardy J, Duff KE. Selective vulnerability in neurodegenerative diseases. Nat Neurosci. 2018;21(10):1350–8. https://doi.org/10.1038/s41593-018-0221-2.CrossRefPubMedPubMedCentral

Titel: Molecular Imaging of the Cholinergic System in Alzheimer and Lewy Body Dementias: Expanding Views
verfasst von: Prabesh Kanel
Marc-André Bedard
Meghmik Aghourian
Pedro Rosa-Neto
Jean-Paul Soucy
Roger L. Albin
Nicolaas I. Bohnen
Publikationsdatum: 01.10.2021
Verlag: Springer US
Erschienen in: Current Neurology and Neuroscience Reports / Ausgabe 10/2021
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-021-01140-z

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2021

Current Understanding of the Pathophysiology and Approach to Tension-Type Headache

Dietary Insights in Neurological Diseases

Cerebrovascular Complications of Anemia

Management of Intracerebral Hemorrhage: Update and Future Therapies

The Ties that Bind: Agnosia, Neglect and Selective Attention to Visual Scale